Atreca is a biotechnology company developing novel therapeutics drawn from human immune responses, including effective anti-Âcancer immune responses. We are able to measure and analyze the structure of clinically relevant immune responses to identify the antibodies, T cell receptors, and targets that are key to successful treatment outcomes. Atrecaâs proprietary Immune Repertoire CaptureÂŽ technology profiles a patientâs immune response at the single-Âcell level at very high throughput essentially without bias or error, enabling the identification and generation of functional human antibodies and TCRs without prior knowledge of antigen. The Company is advancing a pipeline of candidates designed to engage the human immune response in oncology and other indications, thus driving better therapeutic outcomes. Source
No articles found.
Eagle is a specialty pharmaceutical company working to advance safe and efficient ...
Eagle is a specialty pharmaceutical company wor...
Siemens Healthineers AG is the holding company of the Siemens Healthineers group. ...
Siemens Healthineers AG is the holding company ...
Ligand is a biopharmaceutical company focused on developing or acquiring technolog...
Ligand is a biopharmaceutical company focused o...
Leap Therapeutics (NASDAQ: LPTX) is focused on developing targeted and immuno-onco...
Leap Therapeutics (NASDAQ: LPTX) is focused on ...
Evoke Pharma, Inc. (NASDAQ: EVOK) is a specialty pharmaceutical company focused pr...
Evoke Pharma, Inc. (NASDAQ: EVOK) is a specialt...
Oramed Pharmaceuticals (NASDAQ: ORMP) was established in 2006, and has developed a...
Oramed Pharmaceuticals (NASDAQ: ORMP) was estab...
Merus is a clinical-stage immuno-oncology company developing innovative full-lengt...
Merus is a clinical-stage immuno-oncology compa...
Join the National Investor Network and get the latest information with your interests in mind.